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Conclusions: This is the ﬁrst description of PA CL-resistance in Italian CF patients.
Although in very low percentage (2.2 %) this emergence needs concern in the
extensive and prolonged use of this important therapeutic option. Moreover, in the
CF microbiology workout, seems to be mandatory the CL (or polimixin B) routinely
testing in all PA isolates.
P25* PSEUDOMONAS AERUGINOSA (PA) FROM CONTAMINATED
SWIMMING POOLS: A SOURCE OF ACQUISITION FOR CYSTIC
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Background: The initial source of PA acquisition remains unknown in most CF
patients (pts), but the environment is one of the possible sources. Water is the
natural habitat for PA, but at the moment, there are limited published data about
the prevalence of PA in swimming pools and the real risk of acquisition for CF pts.
Aim: Characterize PA recovered from swimming pools, in order to determine
genetically similarity with strains isolated from CF pts.
Methods: A collection of 30 strains from 7 swimming pools of Ligurian region,
isolated by the ARPAL Microbiology Laboratory, were characterized for antibiotic
resistance and hypermutable (HMP) phenotype by disk-diffusion and E-test (Macia
et al 2004). All strains were genotyped by Box-PCR (Rademarker J.L.W, et al
1998) and the genetically relatedness was assessed by Gel Compare II analysis. A
comparison with 240 previously genetically characterized strains isolated from 121
pts of Genova CF Centre was performed.
Results: All the strains were susceptible to Ciproﬂoxacin, Tobramycin and Colistin,
the antibiotic resistance (%) was: Meropenem 20, Gentamicin 7, Ceftazidim 3,
Piperacillin/Tazobactam 3, Ticarcillin/Clavulanate 3, Amikacin 3, Ticarcillin 3 and
Aztreonam 3. 1/30 (3%) strain showed a HMP phenotype. By Box-PCR a total of
16 genotypes were found: 11 genotypes were not shared, while 5 were shared. In
particular 5 clusters were found, with different size of swimming pools: 3 of 2 and 2
of 3. No genetic correlation was observed between swimming pools and CF strains.
Conclusions: This study shows that PA recovered from swimming pools have a
phenotype with low resistance to antimicrobial agents and a low occurrence of HMP
strains. Our results show that a large number of different PA genotypes are present
in swimming pools of Ligurian region. Although our data did not demonstrate any
PA genotype shared by CF pts and swimming pools strains, care should be taken
anyway suggesting CF pts to attend any swimming pool.
*This Poster has been presented also as Oral Communication, by invitation of
the Scientiﬁc Committee
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PATIENTS: RESULTS OF A MOLECULAR STUDY
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Introduction: Achromobacter xylosoxidans (A. xylosoxidans) has been increasingly
recognized as a cause of respiratory tract colonization in Cystic Fibrosis (CF). The
pathogenic role of this Gram-negative bacteria is yet unclear. The present study
was conducted to investigate the epidemiology of A. xylosoxidans isolates recovered
from CF patients. Misidentiﬁcation of A. xylosoxidans can occur, therefore the pres-
ence of respiratory tract infections caused by this bacteria might be underestimated.
Epidemiology of A. xylosoxidans in CF is not well understood: it can cause
temporary or persistent infection in the respiratory tract. A total of 55 isolates
were detected persistently in 8 out of 260 CF patients over a prolonged period of
time (from 2 to 8 years).
Aims: Sequential A. xylosoxidans strains of 8 CF patients were genotyped in order
to detect if these patients are persistently colonized, or whether a cycle of acquisition
and clearing has occurred.
Methods: Lactose-negative on McConkey agar and oxidase-positive colonies were
ﬁrstly identiﬁed using API20NE (bioMerieux), then conﬁrmed by PCR. This
molecular method allows to identify A. xylosoxidans recovered from CF patients
sputum with a sensivity of 100% and speciﬁcity of 97%, in order to distinguish
A. xylosoxidans isolates from several related glucose non-fermenting species.
Bacterial isolates were ﬁngerprinted by RAPD-PCR.
Results: Three out of 55 (5.5%) isolates were uncorrectly identiﬁed as A. xylosox-
idans and were not included in the epidemiological study. Isolates collected from 5
out of 8 patients exibited identical RAPD proﬁles, indicating that the same strain
persisted in the lungs of these patients. The remaining three patients are alternatively
colonized by few (2 or 3) different genotypes.
Conclusions: In an attempt to detemine whether CF patients acquired a single
isolate that they kept for years, or were periodically recolonized, serial isolates on a
subpopulation of 8 patients were examined. It appears that the majority of patients
(62.5%) have unique isolates, and only few patients are colonized by more than
one genotypes. A better understanding of the epidemiology of A. xylosoxidans may
help us to clarify the pathogenic potential of this unusual Gram-negative bacteria
in CF lung disease.
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Introduction: Pseudomonas aeruginosa is the most important opportunistic
pathogen in Cystic Fibrosis (CF) patients. The presence in P. aeruginosa of acquired
metallo-b-lactamase (MBL), that confers broad-spectrum resistance to b-Lactam
antibiotics, represents an alarming phenomenon in clinical practice. Acquired
resistance determinants in patients with CF are not commonly found and blaIMP
genes have never been described. In this study we report about the ﬁrst identiﬁcation
of an IMP-type MBL in isolates of P. aeruginosa from a CF patient.
Methods: Isolates of P. aeruginosa with a proﬁle suggesting the production of MBL
collected from eight patients attending the Ospedale Bambin Gesu` in Rome have
been analysed. Hybridization, PCR and DNA sequencing have been used to detect
blaIMP genes. Retrospective isolates have been included in the study. Clonality of
strains producing MBL have been analysed by genotyping work (RAPD/PFGE).
Results: From one out of eight patients (an 8-year-old girl), a P. aeruginosa strain
producing an IMP-type resistance determinant, encoded by the gene variant blaIMP
has been isolated. The analysis of the retrospective isolates from the patient, as
well as their clonality, demonstrated the persistence of the isolate producing IMP-
13 along a period of 3 years. Besides, the analysis has highlighted the presence
of this resistance determinant since the ﬁrst time the patient has been colonized
by P. aeruginosa. The clinical course of the patient has been characterised by
pulmonary exacerbations, with a slow but progressive decline of pulmonary function
(FEV1: 88%) despite repeated antibiotic cycles (aminoglycosides and quinolonics).
Conclusions: Metallo-b-lactamase (MBL) blaIMP, widespread in Italy, has been
isolated for the ﬁrst time in P. aeruginosa strains from a patient with CF. This is an
alarming phenomenon which can have important implications for the therapeutic
as well as the surveillance ﬁeld.
P28 “ANGELA’S CASE”
P. Catastini, S. Magni, M.C. Cavicchi, T. Repetto, C. Braggion. C.F. Center Meyer
Hospital, Florence, Italy
Background: We would like to introduce the clinical case of “Angela”, an Albanian
girl aged 24 months, who has been diagnosed by neonatal screening at our CF
Centre (Meyer Hospital, Florence, Italy).
Following and taking care of A. and her family represents and has represented since
CF diagnosis moment a very difﬁcult engagement because of the many unsuccessful
attempts of creation of a good collaborative relationship with A.’s parents. Our
difﬁculty is mainly correlated to the mother’s parental and attachment style that has
not permitted to understand for certain how she takes care of A. and manages her
daughter’s illness.
We hypothesize that the mother needs to consider the symptoms of her child as CF
related even if there is no clinical evidence. This hypothesis originated from the
different communications that the mother usually gives to the various operators of
the CF Centre about what happens to A. and how she faces the different illness
aspects and moments; doing that she shows an ambivalent relational style: frequent
treatment requests accompanying the difﬁculty or incapacity to follow the medical
indications, for instance she requested invasive medical checks for A. because of
abdominal-ache and at the same time she gave A. coke or other drinks with gas;
she did not confess that frankly but she minimized what happened when we asked
information about that. Moreover we have the perception of high risk for A.’s
physical and psychological health: she keeps facing many hospitalizations because
of ruinous situations of frequent vomiting and loss of weight that turn out well with
adequate therapy and controlled diet in a few days in hospital.
Clinical situation and clinical course: pancreatic insufﬁciency; frequently hospi-
talization for vomit, food refuse and very important weight loss; pulmonary disease
without main infection exacerbations, not Pseudomona aeruginosa colonisation.
During last hospitalization, for recurrent vomit and weight loss, we tried to perform:
– Esophageal pH 24 hours monitoring: not concluded because A. take off the tube;
– Gastrointestinal contrast radiographic study on narcotic state;
– Endoscopy, and ultrasound only showed a medium gastroesophageal reﬂux;
– Physiotherapy programme; feeding programme; pancreatic and antiacid therapy,
family psychological support.
Discussion: We ask ourselves how and how much it is necessary to protect A. from
her mother’s nurturing style by more important interventions to control the mother’s
psychological capacity about her role in the relationship with her daughter and in
the management of the illness.
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Our doubt: could a more incisive intervention for the protection of A.’s development
have the risk of a further invalidation of the mother, if the hypothesis about her
pathological psychological condition is correct?
Conclusion: After frequent attempts of creation of a better relationship with A.’s
parents we must evidence our failure: we did not ﬁnd the adequate way to manage
this case and we feel blocked between the comprehension of the mother’s difﬁculties
about her daughter’s illness and the hypothesis of Munchausen syndrome by Proxy,
or recognize the possibility of the mother’s psychiatric pathology.
She is currently separated from her husband and has refused the aid of a social
worker, eliminating any presence in the relationship between her and child. However
she continues to present an inadequate management of her daughter who has a
serious nutrition condition.
P29 COMMUNICATION OF DIAGNOSIS TO CHILDREN: MEDICAL
ROLE
C. Risso, G. Cordola, I. Tardivo A. Veljkovic. Pediatric CF Centre, O.I.R.M. Turin,
Italy
When we speak of “communication of diagnosis” we usually mean the situation
in which the physician communicates to parents that their child is suffering
from cystic ﬁbrosis. Literature contains lot of articles facing this thematic from
the psychological point of view. Seldom has been considered the importance to
communicate and to give information to the child. Obviously during the ﬁrst years
of his life the child is not aware of illness, and he faces it through the emotions
of the adults. Therefore he is inﬂuenced by the feelings of his mother or other
important referee. When he becomes three-four years old he becomes aware of the
disease and, additionally, of his own body; he begins to be sensitive to the offered
explanations about the necessity of the visits, of the therapies or of the hospital
admissions and overall he needs to be informed about his performance status of
health avoiding to feel guilty for the disease and to feel therapies as maltreatments.
Beginning from this phase of development and even more afterward, too often are
parents to bear the responsibility to give answers and explanations to the children,
not always satisfactorily supported and helped by the health team of the Center. We
think, instead, it should be very important that physicians themselves must put up,
with the small patients, a good relationship characterized by unambiguous, sincere
and continual communication adapting it to the age of the child.
The communication of diagnosis is not a ﬁnishing event that reaches ends con-
clusions, but rather a never-ending situation that begins in the childhood and it
continues in the growing years.
If, meeting the child, we speak to him basically, explaining his disease and what
we are planning to do just to cure him and moreover we listen to his fears and we
answer his questions, only in this case we demonstrate respect to him as a human
being liberating him by a negative function of inactive object and beginning to build
a correct therapeutic strategy.
With this approach even a hard event, like a hospital admission, will not be
considered as a tragic experience to be removed but rather as an unavoidable
necessity without any alternative choice.
At last, the health staff should be aware of what kind of information about the
disease has been given to the patient by the parents, because a common strategy
should be planned together and implemented in concert. Resistances of the family
and the possible inclination to reject to speak to the child about illness should be
respected but as well discussed together.
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Introduction: The psychological, physical, and social impact of CF is complex and
varies among patients of different ages. In the last decade, health-related quality
of life (HRQoL), deﬁned as the "people subjective evaluation on the inﬂuences of
their current health status on the ability to achieve and maintain a level of overall
functioning" has become an essential outcome for chronic conditions.
This study is aimed at assessing HRQL in Italian CF patients cared for at the
Bambino Gesu` Children’s Hospital.
Patients and Methods: The inclusion criteria were: being regularly followed up,
7 years of age, ability to read Italian and absence of mental illness.
The age-speciﬁc versions of the Cystic Fibrosis Questionnaire (CFQ; Henry et
al, 1996) were used with permission. They were translated into Italian, and back-
translated into the original language (French) to check for semantic equivalence.
Higher scores indicate better quality of life.
Results: Out of 121 eligible patients, 118 accepted to participate (97.5%). Forty-
eight (40.7%) were aged 7−13 years; 27 (22.9%) were 14−17 years old, and 43
were 18 years or more (36.4%). Fifty-one percent were females.
Patients consistently reported scores higher than 70 on most of the domains.
Lower scores were obtained in “Treatment Constraints” and “Social Limitations”
sub-scales. Compared with older patients, younger ones had higher scores on
“Energy/wellbeing”, and lower on “Social Limitations”, “Eating Disturbances” and
“Digestive Symptoms”.
As expected, patients with the most compromised lung functioning (FEV1 <65)
showed lower HRQL scores, particularly in “Emotional functioning”, “Body im-
age”, “Treatment constraints” and “Respiratory symptoms”. No gender-related
differences were found.
Conclusions: HRQoL domain of “Social limitations” appears of most concern in
children and adolescents affected by CF, as “Treatment constraints” in patients with
compromised lung function.
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SFHR (Small Fragment Homologous Replacement) is a gene targeting strategy
based on homologous recombination (HR) of small DNA fragments (SDFs) into
the genomic DNA of recipient cells. The SFHR technique has also been applied
to modify the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)
gene. The inadequate knowledge of the mechanisms of action of the SFHR limits
its reproducibility and efﬁciency. The relevance of SFHR for the correction of
CFTR defects, together with the still unexplored possibility of an inﬂuence on HR
of epigenetic DNA modiﬁcations, prompted us to investigate the effect of SDF
methylation on SFHR-mediated gene repair process efﬁciency.
We used our previously constructed assay system obtained by stable integration of
a mutated copy of enhanced green ﬂuorescent protein (EGFP) gene in immortalized
embryonic ﬁbroblasts DNA.
The SFHR efﬁciency was quantiﬁed by FACS analysis as the percentage of EGFP-
positive cells after correction. The effect of methylation status of the corrective frag-
ment was tested by comparison between PCR-ampliﬁed and plasmid-excised SDFs.
The presence of methylation on SDF was checked by digestion with methylation-
sensitive restriction enzymes, followed by PCR ampliﬁcation: the presence or ab-
sence of a PCR amplicon indicates, respectively, a methylated or unmethylated SDF.
In plasmid-excised SDF, we evidenced both DAM and DCM, but not HpaII,
methylation. No methylation was evidenced on PCR-ampliﬁed SDF. When a PCR-
ampliﬁed (unmethylated) SDF was transfected in cells synchronized in G2 phase,
the efﬁciency of correction was 0.1%. After transfecting a plasmid-excised (methy-
lated) SDF, a 15-fold increase of ﬂuorescent cells was evidenced, reaching 1.5%
of correction. Also the effect of speciﬁc methylation patterns, created on the SDF
fragment by treatment with speciﬁc methylases, was evaluated and will be discussed.
The 12% of residual CFTR functionality is usually accepted as the lower threshold
to be overcome to restore a normal phenotype in Cystic Fibrosis patients: the en-
hancement of SFHR efﬁciency due to SDF methylation opens up a new perspective
for the correction of mutated CFTR.
*Tel 06–49970458, Fax 06–4464698, E-mail lucarelli@bce.uniroma1.it
This work and G.F. were partially supported by “Fondazione per la Ricerca sulla
Fibrosi Cistica” (grant FFC 5/2005).
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Pseudomonas aeruginosa infection and chronic inﬂammation are hallmarks of lung
disease in cystic ﬁbrosis (CF).
Extracellular GSH is a scavenger of free radicals produced by neutrophils in
inﬂamed tissues.
Glutathione transferases (GST) are a superfamily of dimeric proteins which conju-
gate glutathione to a wide range of substrates including oxidants and are involved
the synthesis of leukotriens.
Azithromycin (AZM) ameliorates lung function in cystic ﬁbrosis (CF) patients. This
macrolide has been suggested to have anti-inﬂammatory properties as well as other
effects potentially relevant for therapy of CF.
The present investigation was aimed to verify the effects of AZM on GST activity
in CF cell lines.
